Ed Silverman
Senior Writer at STAT
Columnist at Pharmalot Newsletter
Pharmalot columnist and senior writer at @STATnews.. former WSJer.. proud dad; likes music, dogs and taking naps
Articles
-
2 days ago |
statnews.com | Daniel Payne |Ed Silverman
WASHINGTON — President Trump’s executive order to lower drug prices through sweeping, cross-agency action left leaders in the pharmaceutical industry scrambling Monday to make sense of what may be ahead — and how to respond. The announcement was long on messaging, but short on details. That may explain why share prices for many pharmaceutical and biotech companies dropped in the hours before the announcement, but gained ground after investors took stock of Trump’s moves.
-
3 days ago |
statnews.com | Ed Silverman
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and messages has returned. But what can you do? There is no pause button to stop the world from spinning. So this means one thing: time to dig in to the tasks at hand. On that note, we have assembled a menu of tidbits to help you get started. Meanwhile, we have also fired up the coffee kettle for another cup of stimulation.
-
5 days ago |
statnews.com | Ed Silverman
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week. This time around, we note that Zealand Pharma hired Utpal Singh as chief scientific officer.
-
5 days ago |
statnews.com | Ed Silverman
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda involves saluting our shortest person — aka the scholar — on completing her studies with distinction. This will call for a special listening party, where the rotation will likely include this, this, this, this and this. And what about you? This is a wonderful time to enjoy the great outdoors.
-
6 days ago |
statnews.com | Ed Silverman
Medicare drug plans significantly boosted coverage of biosimilar versions of the Humira rheumatoid arthritis medicine this year, but nearly all of them failed to take steps that would encourage greater use of these alternative treatments, a new government watchdog report finds. The report found that 96% of the Part D plans and 88% of the Medicare Advantage drug plans agreed to cover at least one of the 10 available copycat drugs on their 2025 formularies.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 5K
- Tweets
- 281
- DMs Open
- No
FDA scolds Merz over ‘misleading’ Instagram posts featuring interior designer Nate Berkus.. https://t.co/1yetrqOj68… #pharma #FDA #botox #wrinkles #Instagram
Student group that ranked med schools over industry conflicts votes to accept pharma funding.. https://t.co/Oy0tDXJaYA #pharma #medicine #MedicalEducation #medschool #conflicts
““The whole purpose of biosimilars was to introduce competition into the marketplace," said study author Ben Rome. "...The fact that it’s so hard to find savings consistently is disappointing." https://t.co/2VZjM2l1NL #pharma #biotech #biologics #biosimilars #medicines